Prostate Cancer

Update provided on KRX-123

Published in Cancer Weekly, January 21st, 2003

Keryx Biopharmaceuticals, Inc., (KERX; KRX) announced that it intends to request a preinvestigational new drug (pre-IND) meeting with the FDA to discuss the clinical development of KRX-123, a peptide drug candidate for the treatment of hormone refractory prostate cancer (HRPC).

Specifically, Keryx believes that the mechanism of a pre-IND meeting will enable the company to discuss with the FDA matters related to the formulation strategy for the clinical trials of KRX-123. As the company has previously stated, Keryx had encountered challenges in formulating KRX-123.

Recently, Keryx has developed several innovative approaches for formulating KRX-123...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry